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DFT: Density functional theory????????
3′-FTD: 3’-Fluorothalidomide????????????
3′-FTD[n]: The n-th generation hydrolytic products of 3’-FTD?3’-FTD?? n?????????










P450: Cytochrome P450?????? P450?
PD: Pomalidomide????????




TD[n]: The n-th generation hydrolytic products of TD?TD?? n?????????
TD-DFT: Time dependent density functional theory?????????????
tR: Retention time??????

















???????????? [Laska and Teubner, 1999]????????????????????
???????????????????? D-??????????????????????
??????????D??????????????????????????? [D’Aniello
et al., 1993,Wade et al., 1990]???? D-Ser? D-Asp???????????????????
?????????????????????????????????????? [Tsai et al.,
1998,Nagata et al., 1999]?
??????????????????????????????????????????
???????????????????????2000??????????????????
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????????? λ?????????? ∆ελ?????? 0??????????????
? a??????????????
∆ελ ∼ R0a = Im⟨0|µˆ|a⟩ · ⟨a|mˆ|0⟩ (1.1)
????? [Rosenfeld, 1929]???? (1.1)??? ⟨a|µˆ|b⟩??????????????????




drφ∗0(r, t)µˆφa(r, t), (1.2)
⟨a|mˆ|0⟩ =
∫
drφ∗a(r, t)mˆφ0(r, t) (1.3)
????????? µˆ = −e∑neli=1 rˆi, mˆ = (−e/2mc)∑neli=1(rˆi × pˆi), pˆi = −i!∇ˆi????rˆi? pˆi????
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?????????????????? [Harada and Nakanishi, 1972,Taniguchi and Monde, 2012]?
CD????????????????????????????????????????
???????????????????????????????????? (TD-DFT)??
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???????????????????????????? [Nishimura et al., 1994]?Blaschke
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? 1.6: TD?????3’-FTD?PD?? LD?????
???????????????????????????????2014????TD? CRBN
??????????????????CRBN?? TD??????????????????
??????TD??????????????????? [Fischer et al., 2014]??? PD? LD
? CRBN?????????????????CRBN???????????????????









??????????????????????? [Suzuki et al., 2010]????????TD??
3’-FTD??????????????????????? [Maeno et al., 2015]????????
???????????????????????????????????????????
???????????????????????????????????????????
?????????? [Soloshonok, 2006]?TD? 3’-FTD??????????????????
???????????????????????????????????????????
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???????? [Tian et al., 2012]?????1. TD??????? TD???????????
????2. ????????????????????????3. ??????????????
????????????????????????????????????????????
???????????????????????????? 73 kcal mol−1??????????




et al., 2007]??????????????????? α-(2-carboxybenzamide)glutarimide (CBG)?
???????????????? TD??????????????????????????
???????????????????????????????????????????























































???????????????????????????????? [Denisov et al., 2005,Nebert
and Russell, 2002]?P450??????? Fe-????????????????????????
???????????????????????????????????????????
? 450 nm???????????? P450??????????? [Omura and Sato, 1962]?P450
???????????????????????????????????????2000??
???????????????????????????????????????????







??? P450??????????????????? [Groves, 1985,Ogliaro et al., 2000,Meunier
et al., 2004]?TD??????????????? 4????? 5??????????????













Intermediate cation Intermediate radical
Epoxide Hydroxylated TD Resonance form




???? TNFα????????????? [Nakamura et al., 2006]????? cis/trans-5’-OH-TD
????????????????? TD????????????????TD????????
P450?????????????????????????????????????????
???????????? [Dowers et al., 2004]?? 2.3??????????DNA???????
?????????????? DNA?????????????????????? [Stephens
et al., 2000]?
3′-FTD? PD?? TD?????????????????????? TD????????

















(R)-(+)-?(S)-(-)-?? (RS)-TD???? 258.23????????????????? [Suzuki and
Shibata, 2001,Muller et al., 1999]??? Sigma Aldrich?????????????
3′-FTD???? 276.22?????????????????????? [Yamamoto et al., 2011]?
?????????????????????????????PD???? 273.25??????
? Sigma Aldrich?????????????????????




?????????????????????P450????????? 20 mg mL−1?????
??? (male & female)?CD-1????Sprague-Dawley????????? Sigma-Aldrich???





TD?????????????? (2.58 mg)?3′-FTD?2.76 mg)?PD?2.73 mg???????
1.0 mL??????????? (DMSO)??????? 10 mM??????????????
?? KH2PO4???? 136.09?? 1.36 g??? 100 mL??????????????????
?????K2HPO4? 6.97 g??? 400 mL?????????????????0.1 M????
???????pH 7.4?????1.5 mL?????? TD??????DMSO?? (10 mM) 5 µL












































1.5 mL???????0.1 M???????????pH 7.4?? 55 µL?0.1 mM? EDTA/??
????? 20 µL?????? NADPH?????? 1.3 mM? NADP+/??????? 20 µL?
3.3 mM?????? 6-???/??????? 20 µL?0.4 unit mL−1?????? 6-??????
??/??????? 20 µL?3.3 mM?MgCl2/???????????????????????
???????????????????? 5 µL?????????????????????
????100 µM?? 40 µL???????? 200 µL???????? TD??????????












?????? SiliaPrepX HLB?????? 30 mg/1 mL?Silicycle???? Strata-X??????
30 mg/1 mL??????????????????SiliaPrepX HLB???????????? 1?
Strata-X???????????? 2?????
???? 1






????????????????????? 1.0 mL???? 1.0 mL???????????
???????????? 200 µL????????????????????????????
????????????????????????? 50%????? 1.0 mL????????





????????? TD?????? (R)??????? i????? j??????????
? (i, j)R ????? 2.5??LC-MS/MS????????????????????? (i, j)??
????? (1, 0)????????????????TD??????? PiG?PG?? CBG??
?????(0, 0)????? TD????????TD????????i? j?????????
????? i = 0, 1, 2, 3, 4? j = 0, 1, 2??????????????????????????
???? (i, j)R −→ (i, j)S?(i, j)R −→ (i + 1, j)R?(i, j)R −→ (i, j + 1)R???????????? z
???? [M ± zH]z±???????? (i, j)??? M????????????? M0????
M = M0 + 18i+ 16 j± z??????????m/z = (M0 + 18i+ 16 j± z)/z???????????
?????????????????????????????????m/z = M0 + 18i+ 16 j± 1
???????????????????????????? 2.1?? 2.6????? (i, j)??
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i-th generation hydrolyzed and



















LC-MS/MS??? Shimadzu Prominence HPLC system???????????????? AB
SCIEX TripleTOF system mass spectrum?AB SCIEX????????????????????
???????????????????CAPCELL CORE ADME?????????2.1? 100
mm???????
????????????????????????????A????????/? = 5/95 (v/v)
?0.1% HCOOH??? (v/v)??????? B????????/? = 95/5 (v/v)?0.1% HCOOH??
? (v/v)?????0.2 mL min−1??????????0-1?? A:B = 99:1?1-3?? A:B = 99:1?




????????????4.1????????120 ◦C????????325 ◦C????? CE??
????6?
?? TD???????????????????????? (TIC)?m/z 100 - 1000????
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? 2.6: TD???? (i, 0)????? (0, j)??????
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? 2.2: ?? (i, j)????????????????????? m/z?[Ogino et al., 2017]???
????????
(i, j) Compound [M+H]+ m/z (i, j) Compound [M+H]+ m/z
TD 259.07 TD[1] 277.08
(0,0) 3’-FTD 277.06 (1,0) 3’-FTD[1] 295.07
PD 274.08 PD[1] 292.09
OH-TD 275.06 OH-TD[1] 293.08
(0,1) OH-3’-FTD 293.06 (1,1) OH-3’-FTD[1] 311.07
OH-PD 290.08 OH-PD[1] 308.09
Di-OH-TD 291.06 Di-OH-TD[1] 309.07
(0,2) Di-OH-3’-FTD 309.05 (1,2) Di-OH-3’-FTD[1] 327.06
Di-OH-PD 306.07 Di-OH-PD[1] 324.08
TD[2] 278.06 / 295.09
(2,0) 3’-FTD[2] 296.05 / 313.08
PD[2] 293.07 / 310.10
OH-TD[2] 294.06 / 311.09
(2,1) OH-3’-FTD[2] 312.05 / 329.07
OH-PD[2] 309.07 / 326.10
Di-OH-TD[2] 310.05 / 327.08
(2,2) Di-OH-3’-FTD[2] 328.04 / 345.07







??????????????????????? (1, j)???????m/z???? 1??? 18









?????????????????????100 nm min−1??????????27 ◦C???

























?????????? (S)?? TD(m/z 259.07)?????? PiG?PG???CBG(m/z 277.08)?
?????? XIC?? 2.7(a)???????????????TD?? 4.8??PiG?? 4.43??
PG?? 4.38??CBG?? 4.33??????(R)???????? TD????????????
?????TD???? (1,0)???????????????????????????????
?? TD?????????????????????????????????? PiG? PG?
?????????????????????TD? (1,0)?????????????????































? 2.7: (a)TD?? (1,0)?????????????????????????(b)(1,19????
































































? 2.9: ????????????????????????? (0,0)?????? (2,2)????
????????????????????????????????????????????








































? 2.10: ????????????????????????? (0,0)?????? (2,2)????
???????????????????????????????????? 1??????
30?????? (1,0)???????????????????????[Ogino et al., 2017]??
?????????










Chowdhurry ???????? TD ? P450 ???????????????????????
? [Chowdhury et al., 2013]?5??????? TD?????5???????????????
??????????????????????????????????????? 3????
? 6??????????????????????????? (0,2)????????? 2.12??
???????????????????????????????????????????









? 2.11: ?????????????????????? TD?3′-FTD?PD? (0,2)??????







? 2.12: OH-TD???? P450???????????????? [Chowdhury et al., 2013]
?????????????????????3′-FTD???????????????????
????????3′-FTD? 5?????????????????????????????PD























?????? TD????????????? (1,0)???????????? (1,0)?????
P450????????? 5??5’????????? (1,1)???? G???????????




PiG??????PG? (S)??CBG? (S)???????????? 60?????????(1,1)
????????????? XIC?? 2.14(a)??????????????? 2.14(b)????























? 2.14: (a) (1,0)?????????? P450??????????? XIC(m/z 293.07)?(b) TD?
PiG?PG???? CBG????????????????????????? (1,1)?????








????????5-OH-TD????????????????? [Yamamoto et al., 2009]???
4-OH-TD? N-OH-TD? in vitro?? in vivo???????????????????? [Ando










? 2.15: (R)??? (S)?? TD????????????? 1???????? 60??????

























Theoretical rotatory strength 
((S)-5-OH-TD)




















E = -987.37068269 a.u.
E = -987.36787460 a.u.
(a) (b)
? 2.17: (a)cis-5’OH-TD? trans-5’OH-TD???????????? CD??????????
???????????????(b)cis-5’OH-TD ? trans-5’OH-TD ????????????













??? 2.16?? 2.17??? 2.18??5-OH-TD??????????????????336 nm?
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E = -1063.83101602 a.u. E = -1063.82134645 a.u.
E = -1063.84149725 a.u.
(a) (b)
? 2.18: (a)5-OH-CBG?cis-5’OH-CBG? trans-5’OH-CBG????????????CD????
?????????????????????(b)5-OH-CBG?cis-5’OH-CBG? trans-5’OH-CBG















? 2.19: cis-5’OH-TD?trans-5’OH-TD?5-OH-CBG?cis-5’OH-CBG? trans-5’OH-CBG????










• 3′-FTD? PD???? TD?????????????????????????????
????????????? TD???????????



































? 250 mm???????????????????/??????? = 80/20 (v/v)????0.5 mL
min−1???????25 ◦C???????10 µL????UV?222 nm???? LC-MS/MS???
????????????????????DAICEL IA-3 (4.6? 150 mm????????????







?????????????????? HPLC????????? 2.20(a)????tR = 7.8?




????????????????????????????????k(0,0)enant = 2.1 × 10−1 h−1?
























? 2.20: (a) ????? 10-60?????? TD??????????? HPLC????????
(b)???????? TD?????????????????????????????? log
?????n = 3?mean? SD??(c)????? 10-60?????? (1,0)???????????
???????????????????(d)???????? (1,0)????????????
?????????????????????? log?????n = 3?mean? SD??
?????????????????? m/z 277.08??????? XIC?? 2.20(c)????
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????????????????????????????????????? [Maeno et al.,
2015]?3′-FTD???????? TD???? 20?????????????????????
???????????????????????????????????????????




???????????????????? [Katagiri et al., 1968,Tsai et al., 1970,Lipscomb et al.,

























































































??????????????P450cam (= CYP101)????????? Pseudomonas putida??
?????????1985????????????????? P450??? [Poulos et al., 1985]?
P450cam? d-?????? 5????????????????????????? exo???
?????????TD??????????? 5’?????????????????????
???? 5’??????? cis???? trans?????????????? trans??????
????3′???????????????????????????? cis?????????
??????????????? [Yamamoto et al., 2009]??????????????????
???????????????????????????????????????????
???????????????????????????????????????????
???????????????????????? [Bathelt et al., 2008]????? 2.3?????
Bathelt???????? P450???????????????????P450????????









P450????? Fe?????????? S = 5/2??????? S = 3/2?????????
??????????????????? [Shaik et al., 2002, Shaik et al., 2008]????????
???????????????????????????????????????????
?????????????????????? Cpd I??????????????????
??????????????? 3.3??? R? Cpd I???????????????????
?????????4P?????????????2P???????????????????












High-spin state Low-spin state




??????TD??????????? 2C19? 2C9?2B6???????? 3A4? 3A5???
????????????? [Ando et al., 2002, Lu et al., 2004]??? 2C19? 3A4??????
TD?????????????????? [Ando et al., 2002,Lu et al., 2004]?????????
????????????????????????????????????????? X?
???????????????????????????????????????????
????????????????????? [Hosfield et al., 2003,Das et al., 2010, Fischer et al.,

















????????? Autodock [Morris et al., 2009]?????????????????????
??????????????????Gold [Jones et al., 1995, Jones et al., 1997]?Glide [Friesner
et al., 2004,Halgren et al., 2004, Friesner et al., 2006]?Surflex-Dock [Spitzer and Jain, 2012]?DOCK
















PDB?????? (http://www.rcsb.org/pdb/)?? 2C19 (code: 4gqs) [Reynald et al., 2012]? 3A4
(code: 4d75) [Kaur et al., 2016]???????? PDB??????????2C19? 477???
???????????????????????????? 53%?β?????? 6%????
???? 3A4? 487??????????????????????????????? 49%?
β?????? 7%??????? 4gqs?????????? (4-Hydoroxy-3,5-dimethylphenyl)(2-
methyl-1-benzofuran-3-yl)methanone (0XV)?????????????????????????
???????????? (Apo-2C19)??????? 3.4(a)????? 4d75??????????
tert-Butyl{6-oxo-6-[(pyridin-3-ylmethyl)amino] hexyl}carbamate (PK9)?????????????
???????????????????????? (Apo-3A4)??????? 3.4(b)??????
????????????????????????? induced fit?? [Koshland, 1958,Koshland,
1995]????????????????????????????????????????4gqs
? 4d75?????? 0XY? PK4???????????????????????TD???
???????????????????????????4gqs? 4d75?????? Apo??




?????????????? TD?(1,0)???? PiG?PG?CBG??????? 3′-FTD?
???????????????????????????????????????????
??????? [Suzuki et al., 2010,Maeno et al., 2015, Otogawa et al., 2015]?(2,0)??????



















? 3.1: 2C19?? 3A4?????????????????
2C19 3A4
???? ?????? ???? ???? ?????? ????
102 Leu B-C Loop 105 Arg —
114 Phe B-C Loop 119 Ser —
204 Asn Helix F 212 Arg —
205 Ile Helix F 304 Phe Helix
208 Val Helix F 309 Thr —
209 Ser — 369 Ile —
293 Asp Helix I
300 Glu Helix I
301 Thr Helix I
366 Leu Helix K-β1-4 loop
476 Phe C-terminal Loop
???????????????????????????????????????????
?????????????????????????????????????? ∆S conf ??
??????????














































???????????????????????? (IRC)???maxpoints=40, recalc=5, calcfc,
maxcycles=20?????????????????????????????????????
??????????????????




3.3.1 ???? 2C19?? 3A4???????????
Autodock??????????????? (kcal mol−1) (Free energy of binding, FEB)?????
??????????????? 100??????????????????
FEB = FIE + FTIE + TFE − USE (3.3)
??? FIE?????????? (Final intermolecular energy)?FTIE????????? (Final
total internal energy)?TFE??????????? (Torsional free energy)?USE????????
?? (Unbound system’s energy)???????????Autodock??????????????
??????????????????????????? FIE? TFE???????? FEB?
????FIE????????????????????TFE???????????????
sp3????????????????????2C19????? 0XV????????3A4??
??? PK9???????????????????????? Ki = exp(−FEB/RT )?????
???????????????????????????R????? 1.987 [cal K−1 mol−1]?
T ??????????? T = 298 [K]????







?????????? [Reynald et al., 2012]?TD? (1,0)??????????????????
??????????????????????2C19? TD???? 2C19? (1,0)??????
???????????????????????????????????????????
?? TFE?????????? FEB???????????????????(1,0)?????
????PiG? PG??? CBG?? TFE?????????????????????????



































































Binding energy (kcal mol-1) Binding energy (kcal mol-1)
-10.0 -5.0 0.0 5.0 10.0 15.0 20.0 -10.0 -5.0 0.0 5.0 10.0 15.0 20.0






























? 3.2: 2C19?????TD???? (S)????????????????????????
?? FEB [kcal mol−1] Ki [uM] FIE FTIE TFE USE Source
TD -7.31 4.38 -7.61 2.14 0.30 2.14 crystal structure
PiG -4.36 639 -6.15 2.15 1.79 2.15 crystal structure
PG -4.58 437 -6.37 2.19 1.79 2.19 crystal structure
CBG -5.70 66.2 -6.60 2.22 0.89 2.22 crystal structure
(2,0) -3.93 1320 -6.61 24.6 2.68 24.6 opt. in silico
FTD -6.85 9.54 -7.15 2.08 0.30 2.08 crystal structure
PD -6.17 30.0 -6.77 2.13 0.60 2.13 opt. in silico

































































Binding energy (kcal mol-1) Binding energy (kcal mol-1)
-10.0 -5.0 0.0 5.0 10.0 15.0 20.0





-10.0 -8.0 -6.0 -4.0 -2.0 0.0 2.0 4.0 10.0
Binding energy (kcal mol-1)
6.0 8.0
? 3.6: 3A4? 3’-FTD?PD??????????????????????????
76
Chapter 3
? 3.3: 3A4?????TD???? (S)????????????????????????
?? FEB [kcal mol−1] Ki [uM] FIE FTIE TFE USE Source
TD -9.07 0.22 -9.37 92.8 0.30 92.8 crystal structure
PiG -9.17 0.19 -10.96 91.0 1.79 91.0 crystal structure
PG -7.48 3.29 -9.27 91.6 1.79 91.6 crystal structure
CBG -8.70 0.42 -9.60 91.3 0.89 91.3 crystal structure
(2,0) -8.33 0.78 -11.01 88.8 2.68 88.8 opt. in silico
FTD -8.14 1.08 -8.44 88.8 0.30 88.8 crystal structure
PD -7.82 1.87 -8.41 89.0 0.60 89.0 opt. in silico
















????????????????(ΔΔG = +0.84 kcal mol-1)
? 3.8: 2C19? (S)-CBG?????????????????????
78
Chapter 3
? 3.4: 2C19?????TD???? (R)????????????????????????
?? FEB [kcal mol−1] Ki [uM] FIE FTIE TFE USE Source
TD -7.34 4.16 -7.64 2.19 0.30 2.19 crystal
PiG -4.87 270 -6.66 2.19 1.79 2.19 crystal
PG -5.07 140 -6.86 2.21 1.79 2.21 crystal
CBG -5.45 101 -6.35 2.20 0.89 2.20 crystal
(2,0) -3.14 5010 -5.82 21.4 2.68 21.4 opt in silico








































??????????????????? [Tian et al., 2012]?????????????????
????????????TD??????? 42.8 kcal mol−1???????????5-OH-TD?
?????? 59.3 kcal mol−1?cis-5’-OH-TD?? 60.2 kcal mol−1?trans-5’-OH-TD?? 60.7 kcal
mol−1?????????????????????????????????????????









































































































? 3.10: TD? 5-OH-TD?cis/trans-5’-OH?????????????????????????









• ????????? (0,0)?(1,0)?(2,0)??????????????? P450??????
??????????
• (0,0)? 2C19??????????? 1?????(1,0)?????? 10−1?? 10−2?(2,0)
?????? 10−3??????????
• 3′-FTD? PD?? TD???????????????????????? TD?????
????????
• 2C19? CBG?????????????????????????? Fe-???????
??????????????????????????????????












? (1,1)?????????????????? (0,0)? (1,0)?(0,0)? (0,1)?(1,0)? (1,1)?(0,1)
? (1,1)??????????????????????????????(1,0)? (1,1)? (0,1)?
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2000,Watanabe et al., 2010,Savic et al., 2007]????????????????????????
???????????????????????????????????????????
???????????????????????????????????????????
?? [Bischoﬀ and Dedrick, 1970,Varon et al., 1995]?? 4.1? 2-???????????????
???X1? X2????????? 1? 2???????????V1? V2????????? 1












= k12X1 − k21X2 (4.2)
???A(t)??? t???????????? 1?????????????????? C1 =
X1/V1,C2 = X2/V2 ??????????????????????????????????
???????????????????????????????????????????




















? 4.2: ?????? i??????????? l????????????? λ???????
????????? x???????????? x???????????????? km, kµ,?




???????????????????? x1, x2, . . . , xN??????????????? R/S
?????????????????????????????? xi?????????????
???? xi???????????????????????????? e1, e2, . . . , eM?????
?????? x?? x′????? en??????????en = (x, x′)?????????x? en
????x′? en???????? 4.2??xi? xi??????????????????????
km? kµ?????? em = (xl, xi), eµ = (xi, xλ)??????????????????????
?????????????????????????? km?? kµ?????????????
km = km, kµ = kµ?????? k′i ??? k′i ????? xi → xi?xi → xi????????????
?????????????????????????? S = (ξi j)1≤i≤N, 1≤ j≤M?????????
S???????????? ξi j = (+1, 0,−1)??e j???? xi??? +1?e j???? xi???
−1?????? 0????????????+1??-1????????? S+1? S−1??????
???? S+1? S−1??????????+1?-1?????????????? S = S+1 + S−1?
????







????????[Ogino and Asahi, 2015]?????







ξi j · k j
∏
n





? [Reist et al., 1998]?????????????????????(4.3)???????????






= fmeti (x1, x2, . . . , xN) + f
inv
i (xi, xi), (4.4)
dxi
dt
= fmeti (x1, x2, . . . , xN) + f
inv
i (xi, xi). (4.5)
???????????????????????? i?????????? (ξim = +1)????
??????????? i?????????? (ξiµ = −1)?????






kµxi, m, µ = 1, . . . ,N. (4.6)
?????????? y j????? e j????????????? e j = (xl, xi)??? y j = xl?
??????????????????i?????????????????????????
???????
f invi (xi, xi) := k
′
i xi − k′i xi. (4.7)
????????????????????????????????????????????






















χ1 − k′1 0 . . . 0









k′1 0 . . . 0





0 0 . . . k′N
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠
. (4.10)
??? χi?????? S−1 [k1 · · · kM]T? i?????????????????? xi?????









? 4.4: (R)-TD???? (S)-TD????????TD????????????????????
?????????????????????????? (i)?(ii)?(iii)? (iv)????????
??????????????????(iii)? (iv)?????????????????????








??????????????? 2 ?????????????? (? 4.5) [Schumacher et al.,








Gln???????????????? (3,0)??????? Glu? PA????????????








???????????[Ogino and Asahi, 2015]???????????
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? 4.1: ???? i??????????????????????????????[Ogino and
Asahi, 2015]?????
i Compound (i, j)
1 Thalidomide (TD) (0,0)
2 Phthaloylisoglutamine (PiG) (1,0)
3 Phthaloylglutamine (PG) (1,0)
4 α-(2-Carboxybenzamido)glutarimide (CBG) (1,0)
5 N-(2-Carboxybenzoyl)isoglutamine (CBLiG) (2,0)
6 Phthaloylglutamic acid (PGA) (2,0)
7 N-(2-Carboxybenzoyl)glutamine (CBLG) (2,0)
8 α-Aminoglutarimide (AG) (2,0)
9 N-(2-Carboxybenzoyl)glutamic acid (CBLGA) (3,0)
10 Isoglutamine (iGln) (3,0)
11 Glutamine (Gln) (3,0)
12 Glutamic acid (Glu) (4,0)
13 Phthalic acid (PA, achiral) (4,0)
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? 4.2: ????????????? k j [h−1] ??????????????? k′i [h−1]?[Ogino
and Asahi, 2015]?????
j k j j k j i k′i
1 0.05 13 0.005 1 0.4
2 0.1 14 0.005 2 5.0 × 10−6
3 0.4 15 0.005 3 5.0 × 10−6
4 0.2 16 0.005 4 5.0 × 10−6
5 0.2 17 0.005 5 5.0 × 10−6
6 0.005 18 0.005 6 5.0 × 10−6
7 0.005 19 0.005 7 5.0 × 10−6
8 0.005 20 0.005 8 5.0 × 10−6
9 0.005 21 0.005 9 5.0 × 10−6
10 0.005 22 0.005 10 5.0 × 10−6
11 0.005 23 0.005 11 5.0 × 10−6
12 0.005 24 0.005 12 5.0 × 10−6
????? e1, e2, . . . , e24????????????
e1 = (x1, x2), e2 = (x1, x3), e3 = (x1, x4), e4 = (x2, x5), e5 = (x2, x6),
e6 = (x3, x6), e7 = (x3, x7), e8 = (x4, x5), e9 = (x4, x7), e10 = (x4, x8),
e11 = (x4, x13), e12 = (x5, x9), e13 = (x5, x10), e14 = (x5, x13), e15 = (x6, x9),
e16 = (x7, x9), e17 = (x7, x11), e18 = (x7, x13), e19 = (x8, x10), e20 = (x8, x11),
e21 = (x9, x12), e22 = (x9, x13), e23 = (x10, x12), e24 = (x11, x12).
TD?????????????????????????????????????????
???????????????????Reist?? TD??????????????????
HPLC????? k ≃ 1.0 × 10−1 h−1??????? [Reist et al., 1998]???????? TD??
?????????????????????????????TD?? PiG?PG?CBG???
??????????????????????????CBG??? (1,0)????????? 5








??????????????????? (k12, . . . , k24)?????????????(1,0)???
?????? TD??????????????????????? 2.5????????????
(1,0)??????????????????????????TD?????????????





= −(k1 + k2 + k3)x1 − k′1x1 + k′1x1 (4.11)
dx2
dt
= k1x1 − (k4 + k5)x2 − k′2x2 + k′2x2 (4.12)
dx3
dt
= k2x1 − (k6 + k7)x3 − k′3x3 + k′3x3 (4.13)
dx4
dt
= k3x1 − (k8 + k9 + k10 + k11)x4 − k′4x4 + k′4x4 (4.14)
dx5
dt
= k4x2 + k8x4 − (k12 + k13 + k14)x5 − k′5x5 + k′5x5 (4.15)
dx6
dt
= k5x2 + k6x3 − k15x6 − k′6x6 + k′6x6 (4.16)
dx7
dt
= k7x3 + k9x4 − (k16 + k17 + k18)x7 − k′7x7 + k′7x7 (4.17)
dx8
dt
= k10x4 − (k19 + k20)x8 − k′8x8 + k′8x8 (4.18)
dx9
dt
= k12x5 + k15x6 + k18x7 − (k21 + k22)x9 − k′9x9 + k′9x9 (4.19)
dx10
dt
= k13x5 + k16x8 − k23x10 − k′10x10 + k′10x10 (4.20)
dx11
dt
= k17x7 + k20x8 − k24x11 − k′11x11 + k′11x11 (4.21)
dx12
dt
= k21x9 + k22x10 + k24x11 − k′12x12 + k′12x12 (4.22)
dx1
dt
= −(k1 + k2 + k3)x1 − k′1x1 + k′1x1 (4.23)
dx2
dt
= k1x1 − (k4 + k5)x2 − k′2x2 + k′2x2 (4.24)
dx3
dt
= k2x1 − (k6 + k7)x3 − k′3x3 + k′3x3 (4.25)
dx4
dt
= k3x1 − (k8 + k9 + k10 + k11)x4 − k′4x4 + k′4x4 (4.26)
dx5
dt





= k5x2 + k6x3 − k15x6 − k′6x6 + k′6x6 (4.28)
dx7
dt
= k7x3 + k9x4 − (k16 + k17 + k18)x7 − k′7x7 + k′7x7 (4.29)
dx8
dt
= k10x4 − (k19 + k20)x8 − k′8x8 + k′8x8 (4.30)
dx9
dt
= k12x5 + k15x6 + k18x7 − (k21 + k22)x9 − k′9x9 + k′9x9 (4.31)
dx10
dt
= k13x5 + k16x8 − (k22 + k23)x10 − k′10x10 + k′10x10 (4.32)
dx11
dt
= k17x7 + k20x8 − k24x11 − k′11x11 + k′11x11 (4.33)
dx12
dt
= k21x9 + k22x10 + k24x11 − k′12x12 + k′12x12 (4.34)
dx13
dt





? 4.6A?? 4.6D?????????? TD??????????????????????
???????????????????? (R)-TD(x1)?????? 100%?????????
????????????????????? (R)-TD???????????????????














































? 4.6: ????????????????????????????? (R)TD??? 100%???
??????????????????????? ∆t = 1.0 × 10−3????(A) TD? (1,0)??
????????????(B) (2,0)??????????????(C) (3,0)??????????
????(D) (4,0)???????????????????? (R)?????(S)???????



























































? 4.7: TD?????? φi????????????????????? ∆t = 1.0× 10−3????
(A) TD(0,0)? (1,0)????? ee??????(B) (2,0)????? ee??????(C) (3,0)??
??? (4,0)???? (Glu)? ee??????(D) ?????????? φ∗i ?????????










????????????????????????????? φ = 1???? φ = −1????
???????????????????????????????????????????
?????? φ = 0???????????????????????????????????
????????????????????????????? φ?????????????
???????????????????? ee = φ∗i ????????????????????
???? t = 104???? ee? φ∗i ????
? 4.7A??? 4.7D??????????????? ee?????????????????
??TD???? ee????? 0????????? TD??????????????????
?????????TD? (1,0)?????????????????????TD? ee????
















? 4.7D??????? TD?????????????????? ee??????????





























1 + 134.6 × k′41.480
, (4.39)
????????????????????????? R2 = 0.998?????????????













1 10-1 10-2 10-3 10-4 10-5 10-6
? 4.8: (1,0)?????????? k′i ??? eeφ∗i ?????????????????????
???????? φ∗2?φ∗3?φ∗4?????????φ∗4??????? k′i ????? φ∗3?????
????????????????????????????????????????????












































? 4.9: PiG??? ee????????????? k1????????? k4?? k5???????
????? k′2?????????????????????????????????????
?????? ee???????PiG?????????? k4? k5?????????????





? 4.10: ???????????????????????????????? ee??????
???????????????????????????????? ∼ 1?? 10−7?????









?????????? (> ∼ 10−1.5 h−1)???????????????? (< ∼ 10−2 h−1)???
?????????? ee??????????10−2 ≤ k1, k4, k5 ≤ 1??????? ee?????
???????????????????PiG??????????????????????
?????????????????????????????????? ee????????








???????????? ee?????????????????????? 10−1.5 ≤ k1 ≤ 1?


































????TD????????? R→ S ? S → R????????????????????
??????????????R → S ? S → R???????? ∆k′1 = −0.1[h−1]??????
????????? [Eriksson et al., 1998]?????????????????????????
????? ee??????????????????????????? k′1? k′1??????
????????????? ee?????????????????????????????
?????????? 4.2??????????φ1(t = 0) = 1???????????????
?? k1 = k′1 = 0.4 [h−1]?????????????????????????????????
??? ∆k′1 = k′1 − k′1????k1 + k′1 = 0.8??????? ∆k′1?????????∆k′1 > 0??
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???????????????? ee???????? ∆k′1 < 0??????? ee?????
?? 4.12A??∆k′1 > 0????? R→ S ???? S → R???????????????(R)??
TD??????????? (R)???????????????? (R)?? TD???????
????????? ee????????????????? ∆k′1 < 0????? S → R????
R→ S ?????????????????(R)?? TD??????????????????
??? (R)???????????????? ee?????????????? 4.12?B?C?
??TD? CBG??? ee?????????
???k1, k′1???????? 0.4 [h−1]?????????????????????????
?????????∆k′1 = k′1−k′1????min{k′1, k′1} = 0.4???????∆k′1?????????
?????????∆k′1 > 0?????????????????? ee???????? ∆k′1 < 0
??????? ee??????? 4.12D???????????????∆k′1 > 0???∆k′1 < 0?
??? ∆k′1????????? ee????????????????????????????
???????????????????????????????????????????
??? (S → R)???????????????????? (R → S )????????????
ee?????????????????? 4.12? E? F???TD? CBG??? ee?????









































Time (h) Time (h)
? 4.12: (A) TD????????? R → S ?? S → R????????TD? (1,0)?????
?? ee????k′1 + k′1 = 0.8?????????????????????????????(B)
(A)???????TD??? ee??????(C) (A)???????CBG??? ee??????
(D) TD????????? R → S (k′1)?? S → R (k′1)????????TD? (1,0)?????
?? ee????k′1? k′1???????? 0.4???????????????????????








? [Nakamura et al., 2007]?????????????? zi?
zi := 1 − i??????????????????????? TNFα????????????? TNFα? (4.40)
????????????????? zi???? 4.3????????????????????

















??????????????????? (ρi, ρi) = (1.0, 1.0) (i = 1, 2, . . . ,N)????????
(ρi, ρi) = (1.5, 0.5) (i = 1, 2, . . . ,N)?????????????????????????????
?????????????????????????????? Z(t)????????? 4.13
????










? 4.3: TD???????? TNFα????????????????[Ogino and Asahi, 2015]?
????
i Compound Activity parameter zi
1 Thalidomide (TD) 0.32
2 Phthaloylisoglutamine (PiG) 0.18
3 Phthaloylglutamine (PG) 0.13
4 α-(2-Carboxybenzamido)glutarimide (CBG) 0.80
5 N-(2-Carboxybenzoyl)isoglutamine (CBLiG) 0.44
6 Phthaloylglutamic acid (PGA) 0.48
7 N-(2-Carboxybenzoyl)glutamine (CBLG) 0.41
8 α-Aminoglutarimide (AG) 0.13
9 N-(2-Carboxybenzoyl)glutamic acid (CBLGA) 0.62
10 Isoglutamine (iGln) c.a. 0
11 Glutamine (Gln) c.a. 0
12 Glutamic acid (Glu) 0.01









? 4.13: (A) Z(t)?????????????????????????????????? (R)-TD
? 100%??? ρi = ρi = 1.0???????????????????????????????
????????? (R)-TD?? (S)-TD? 100%??? ρRi = 1.5?ρSi = 0.5???????????





















???????z1 > 0.6?? tmax? 0???????? Z(t)?????????????????
????Z(t)??????z1??????????z1 < 0.6????? z1???????????
?????z1 = 0.6???????????????????????????????z1 > 0.6





















?????? (4.41)?? ρi? ρi??????????????????????TD?????
???????????????????????????????????????????


















?????? [Honarparvar et al., 2013,Matei et al., 2012, van de Waterbeemd and Giﬀord, 2003,Shen




(4.11)??? (4.34)??????????? x˙ = Ax???????????????????
????i = 1, 2?????????????????????? A?
A =
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎝
−∑3j=1 k j − k′1 0 k′1 0
k1 −∑5j=4 k j − k′2 0 k′2
k′1 0 −
∑3
j=1 k j − k′1 0
0 k′2 k1 −
∑5
j=4 k j − k′2
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠
(4.42)






j=1 k j + k
′
1 0 −k′1 0
−k1 λ +∑5j=4 k j + k′2 0 −k′2
−k′1 0 λ +
∑3
j=1 k j + k
′
1 0
0 −k′2 −k1 λ +
∑5

















j=1 k j + k
′
1 0
−k′2 −k1 λ +
∑5






−k1 λ +∑5j=4 k j + k′2 −k′2
−k′1 0 0
0 −k′2 λ +
∑5
























































k j + k′2
⎞⎟⎟⎟⎟⎟⎟⎟⎠ − k′2k′2
⎫⎪⎪⎪⎬⎪⎪⎪⎭ = 0. (4.43)
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????? ⎛⎜⎜⎜⎜⎜⎜⎜⎝λ + 3∑
j=1




k j + k′1
⎞⎟⎟⎟⎟⎟⎟⎟⎠ − k′1k′1
= λ2 +











k j + k′1
3∑
j=1
k j + k′1
3∑
j=1



























k j + k′1
3∑
j=1
































k j + k′2
5∑
j=4

























(−∑3j=1 k j +∑5j=4 k j)
1
k1/






(−∑3j=1 k j +∑5j=4 k j − 2k′1 + 2k′2)
−1
−k1/





























−∑3j=1 k j+∑5j=4 k j
1
k1








−∑3j=1 k j+∑5j=4 k j−2k′1+2k′2
−1





















































−∑3j=1 k j+∑5j=4 k j−2k′1+2k′2 + c3e−
∑5


























−∑3j=1 k j+∑5j=4 k j−2k′1+2k′2 + c3e−
∑5










C, x1(0) = x2(0) = x2(0) = 0??????c1 = c2 = C/2, c3 = −k1C/2
(−∑3j=1 k j +∑5j=4 k j) , c4 =
−k1C/2
(−∑3j=1 k j +∑5j=4 k j − 2k′1 + 2k′2)???????? PiG????????????
φ∗2 =
−∑3j=1 k j +∑5j=4 k j
−∑3j=1 k j +∑5j=4 k j − 2k′1 + 2k′2 × e
−(2k′1+∑3j=1 k j)t + e−(2k′2+∑5j=4 k j)t
e−
∑3





j=1 k j +
∑5
j=4 k j






(xi + xi) =
∑
ξi j=+1
k j(y j + y j) −
∑
ξi j=+1





(xi − xi) =
∑
ξi j=+1




⎞⎟⎟⎟⎟⎟⎟⎟⎠ (xi − xi). (4.52)
?????






























ξi j=+1 k j
{
y j(t) ± y j(t)
}
?c±i = xi(0)± xi(0)???????w±i (t)? xi(t)± xi(t)??
































? xi(t)??????????????????????????????? (4.55)?? (4.56)??
?????????????????????? exp(−2k′i t)??? xi(t)? xi(t)?????????
?????? i????????????????????? kraci = 2k′i ??????????TD
????φ1 = exp(−2k′1t)?????????? 2k′1???????????1?????????
????????????????? ee???????? kφi = 0.4????2k′i = 10−5(i = 2, 3, 4)
???????????????????????????????????????????
???????2k′1??????????????? ee??????????????????
1???????R→ S ? S → R?????????????????????????????????????
?????????????????????????????????????????????????????
????????kenant ? krac ?????????????????????????????????? krac = 2kenant
?????? [Reist et al., 1995]?
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???????????????????????? [Reist et al., 1995]???????????
????????????????(4.76)?????????????????????????
????????













(1 − φ2i ) (4.57)
??????????? 1 − φ2i ! 0????φi?????????? x˙i/xi − x˙i/xi = 0?????
?????????x˙i = x˙i = 0????????????????????????? i????
????????????????? x∗i ? xi∗??????????????????????
???????????????????????????????????
???? (4.51)??? (4.52)?????????????????????xi ± xi??????
????? exp(−κt)??????????????



















exp(−∆κit) = φ∗theori , (4.59)
??? α∗±i ??????????κ±iρ = min{κ±i1, κ±i2, . . . , κ±iσ(i)}???? ρ ∈ {1, 2, . . . ,σ(i)}????α±iρ












1 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8
1 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8
exponential
1 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8
exponential
exponential




?????????10−2 ≤ δ ≤ 10−7??????ktheorφi ??????????????[Ogino and
Asahi, 2015]???????????




































dφi/dt? t → 0???????????????????????∑σ(i)ν=1 α±iν = 0????????
?????????????????????? ktheorφi ???????i = 1??????????




exp(−κ±iνt) = 1 − κ±iνt + O(t2), (4.61)




2t2 + O(t3), (4.62)







3t3 + O(t4). (4.63)
(4.60)????? κ±iν?????????????ktheorφi ???????? (∆t)−1????????
????????????????? φ∗theori ? ktheorφi ??????????? α±iν? κ±iν?????
???????i = 2, 3, 4???? xi ± xi = ∑σ(i)ν=1 α±iν exp(−κ±iνt)? (4.51)?? (4.52)??????α±iν
? κ±iν??????
?? (4.51)?? (4.52)???????????????????????????TD????
??????????? x1(t) + x1(t)?? x1(t) − x1(t)?
















{x4(t) + x4(t)} = −
11∑
j=8


















????????x4(t) + x4(t)? x4(t) − x4(t)?








































α−42 = −α−41 = 0.30. (4.73)
(4.68)?? (4.69)???????????∑3j=1 k j = 0.55?∑11j=8 k j = 0.02?2k′1 +∑3j=1 k j = 1.35?
2k′4+
∑11
j=8 k j = 0.02????? κ+41?κ+42?κ−41? κ−42??????????????α∗+4 ?α+42 = 0.76?










PiG? PG???? α∗±i ?????????????????????????? 4.4??????
????????????????????????????????????????? α∗±i ?
????????????????????????????? α±11, · · · ,α±Nσ(N)? κ±11, · · · , κ±Nσ(N)
??????????????α±iν? κ±iν???????ktheorφi ? i = 2, 3, 4???????????
????????????????????????? O(t2),O(t3),O(t4)??????????
???????????????????????????? ee??????? kcalcφi ?????
?????ee????????????????????????t = 0???????????




??? ktheorφi,1 ??O(t3),O(t4)?????????? ktheorφi,2 , ktheorφi,3 ????????????????
? kcalcφi (i = 2, 3, 4)???? 2????????? 4.14??????O(t2)???????????
???????????????2????????????????????????????






















































































































????????????????????i > 1??∑α±iν = 0??????????δ2???
??????ktheorφi,1 ????????????????? ktheorφi,1 ? δ??????????????
?? 4.14???? ktheorφi,2 ????????? ktheorφi,2 ????????????
?? =
(∑


















































































































































?????????O(δγ) (γ > 4)? ktheorφi,3 ?????????????????? δ2??????
O(δγ) (γ > 2)??????????? 0????????????ktheorφi,3 ??? ktheorφi,2 ??????
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? 4.4: (1,0)???????? α±iν?κ±iν?? φ∗calci ?φ∗theori ?kcalcφi ?ktheorφi ????????????
?????????? ktheorφi ????????????[Ogino and Asahi, 2015]?????
i 2 3 4
α+i1 -0.33 -0.19 -0.76
α+i2 0.33 0.19 0.76
α−i1 -0.053 -0.075 -0.30
α−i2 0.053 0.075 0.30
κ+i1 (h
−1) 0.55 0.55 0.55
κ+i2 (h
−1) 0.40 0.01 0.02
κ−i1 (h
−1) 1.35 1.35 1.35
κ−i2 (h
−1) 0.40 0.01 0.02
φ∗calci 0.20 0.40 0.40
φ∗theori 0.16 0.40 0.39
kcalcφi (h
−1) 0.40 0.40 0.40
ktheorφi,1 (h




(h−1) 0.403 0.399 0.396
ktheorφi (exponential) (h
−1) 0.404 0.400 0.396
???
(4.76)??????????δ? 0?????? ktheorφi,1 ????????????ktheorφi,2 ? δ? 0
?????? (1/2)ktheorφi,1 ????????????? 1/2????????????ktheorφi,1 ???
???????????????????? ktheorφi,1 ????????exp(−κ±iνt)?O(t3)?????
??????????O(t4)????????? δ?????? ktheorφi ?????????????
?????????? ee????????? δ????????????10−7 ≤ δ ≤ 10−2???
??????????????????δ < 10−7?????????????????? 4.14??
???????????????????????????????????????????
4.14?????δ > 10−2 ??????? ktheorφi ???????????????????????







???????????????????? 4.15?????????????? xi, i = 1, 2, . . . , 8
????? 4.6????????????????????????P450??????? TD??
?????????????????????????????? 4.5?????????P450?
????????????????????????? [Hlavica and Lewis, 2001]???????
?????????????????? n j ∼ 1???????????????????????
??????????? 4.15???????????????????????????????









+ f other1 (x1) + f
inv








+ f other2 (x2) + f
inv
























+ f other6 (x6) + f
inv






+ f other7 (x7) + f
inv






+ f other8 (x8) + f
inv








+ f other1 (x1) + f
inv








+ f other2 (x2) + f
inv












− k9x4 + f other4 (x4) + f inv4 (x4, x4), (4.92)
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? 4.5: ???????????? ki [h−1]?k′i [h−1]?K [mM]?V [µMmin−1]
???? ?? ?????
k1 0.4 K2 5.0 V2 2.0 k′1 0.4
k8 0.08 K3 5.0 V3 5.0 k′2 1.0 × 10−6
k9 0.08 K4 5.0 V4 10 k′3 0.05
k10 0.08 K5 5.0 V5 1.0 k′4 0.1
K6 5.0 V6 1.0 k′5 0.08
K7 5.0 V7 1.0 k′6 1.0 × 10−6
K2 5.0 V2 5.0 k′7 1.0 × 10−6
K3 5.0 V3 2.0 k′8 1.0 × 10−6
K4 5.0 V4 1.0
K5 5.0 V5 1.0
K6 5.0 V6 1.0












+ f other6 (x6) + f
inv






+ f other7 (x7) + f
inv






+ f other8 (x8) + f
inv
8 (x8, x8). (4.96)
????????? ee??????????? 4.16?????????????? (R)-TD?





































? 4.6: ???? i??????????????????????????????
i Compound (i, j)
1 Thalidomide (TD) (0,0)








????? = (1,0)????? (1,1)?????????? (4.97)




















































? {RR,RS , SR, S S }????? [Meyring et al., 2002,Li et al., 2011,Yamamoto et al., 2009,Yamazaki
et al., 2013]???????????(4.4)?????????????????????????





= fmeti (x1, x2, . . . , xN) + f
inv
i (xi, xi) + f
ex
i (xi), (4.99)





















??????????????????????? (1,1)????? in vivo??????????



















?????? [Suzuki et al., 2010, Izumi et al., 2007]??????????? CD????????
?????????????? TD????????????????????????????
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